Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX

被引:95
作者
De Simone, Giuseppina
Vitale, Rosa Maria
Di Fiore, Anna
Pedone, Carlo
Scozzafava, Andrea
Montero, Jean-Louis
Winum, Jean-Yves
Supuran, Claudiu T.
机构
[1] CNR, Ist Biostrutt & Bioimmagini, I-80134 Naples, Italy
[2] Univ Naples Federico II, Dipartimento Sci Biol, Sez Biostrutt, I-80134 Naples, Italy
[3] Univ Florence, Polo Sci, Lab Chim Bioinorgan, I-50019 Florence, Italy
[4] Univ Montpellier 2, Ecole Natl Super Chim Montpellier, UMR 5032, Lab Chim Biomol, F-34296 Montpellier, France
关键词
D O I
10.1021/jm060531j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An approach for designing bioreductive, hypoxia-activatable carbonic anhydrase ( CA, EC 4.2.1.1) inhibitors targeting the tumor-associated isoforms is reported. Sulfonamides incorporating 3,3'-dithiodipropionamide/2,2'-dithiodibenzamido moieties were prepared and reduced enzymatically/chemically in conditions present in hypoxic tumors, leading to thiols. The X-ray crystal structure of the most promising compound, 4-( 2-mercaptophenylcarboxamido) benzenesulfonamide, which as disulfide showed a K-I against hCA IX of 653 nM ( in reduced form of 9.1 nM), in adduct with hCA II showed the inhibitor making favorable interactions with Gln92, Val121, Phe131, Leu198, Thr199, Thr200, Pro201, and Pro202, whereas the sulfamoyl moiety was coordinated to the Zn2+ ion. The same interactions were preserved in the adduct with hCA IX, but in addition, a hydrogen bond between the SH moiety of the inhibitor and the amide nitrogen of Gln67 was evidenced, which may explain the almost 2 times more effective inhibition of the tumor-associated isozyme over the cytosolic isoform.
引用
收藏
页码:5544 / 5551
页数:8
相关论文
共 57 条
[1]   Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX [J].
Abbate, F ;
Casini, A ;
Owa, T ;
Scozzafava, A ;
Supuran, CT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :217-223
[2]   Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide [J].
Abbate, F ;
Casini, A ;
Scozzafava, A ;
Supuran, CT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) :2357-2361
[3]   Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX [J].
Alterio, Vincenzo ;
Vitale, Rosa Maria ;
Monti, Simona Maria ;
Pedone, Carlo ;
Scozzafava, Andrea ;
Cecchi, Alessandro ;
De Simone, Giuseppina ;
Supuran, Claudiu T. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (25) :8329-8335
[4]   A WELL-BEHAVED ELECTROSTATIC POTENTIAL BASED METHOD USING CHARGE RESTRAINTS FOR DERIVING ATOMIC CHARGES - THE RESP MODEL [J].
BAYLY, CI ;
CIEPLAK, P ;
CORNELL, WD ;
KOLLMAN, PA .
JOURNAL OF PHYSICAL CHEMISTRY, 1993, 97 (40) :10269-10280
[5]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[6]   Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX [J].
Casey, JR ;
Morgan, PE ;
Vullo, D ;
Scozzafava, A ;
Mastrolorenzo, A ;
Supuran, CT .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (09) :2337-2347
[7]   Sulfonamides and Sulfonylated Derivatives as Anticancer Agents [J].
Casini, Angela ;
Scozzafava, Andrea ;
Mastrolorenzo, Antonio ;
Supuran, Claudiu T. .
CURRENT CANCER DRUG TARGETS, 2002, 2 (01) :55-75
[8]   Carbonic anhydrase inhibitors.: Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors [J].
Cecchi, A ;
Hulikova, A ;
Pastorek, J ;
Pastoreková, S ;
Scozzafava, A ;
Winum, JY ;
Montero, JL ;
Supuran, CT .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :4834-4841
[9]   Tumor-activated prodrugs - A new approach to cancer therapy [J].
Denny, WA .
CANCER INVESTIGATION, 2004, 22 (04) :604-619
[10]   C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation [J].
Epstein, ACR ;
Gleadle, JM ;
McNeill, LA ;
Hewitson, KS ;
O'Rourke, J ;
Mole, DR ;
Mukherji, M ;
Metzen, E ;
Wilson, MI ;
Dhanda, A ;
Tian, YM ;
Masson, N ;
Hamilton, DL ;
Jaakkola, P ;
Barstead, R ;
Hodgkin, J ;
Maxwell, PH ;
Pugh, CW ;
Schofield, CJ ;
Ratcliffe, PJ .
CELL, 2001, 107 (01) :43-54